Veracity Capital’s Blueprint Medicines BPMC Stock Holding History

Veracity Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,114	Closed	-$548K	–	235
2021 Q4	$548K	Sell	5,114 -1,000	-16%	-$105K	0.22%	112
2021 Q3	$629K	Hold	6,114	–	–	0.27%	95
2021 Q2	$538K	Buy	6,114 +6	+0.1%	+$550	0.12%	141
2021 Q1	$594K	Hold	6,108	–	–	0.27%	102
2020 Q4	$685K	Sell	6,108 -4,000	-40%	-$422K	0.36%	87
2020 Q3	$937K	Hold	10,108	–	–	0.53%	61
2020 Q2	$788K	Sell	10,108 -10,094	-50%	-$683K	0.45%	63
2020 Q1	$1.18M	Hold	20,202	–	–	0.34%	66
2019 Q4	$1.62M	Buy	+20,202	New	+$1.51M	0.42%	72

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Veracity Capital's BPMC Position: Q1 2022 in Review

Veracity Capital sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 5,114 shares — an estimated $548K sold.

Veracity Capital first reported a position in BPMC in Q4 2019 and held it in 9 quarters. The position peaked at $1.62M in Q4 2019. 249 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

Veracity Capital reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
Veracity Capital sold 5,114 Blueprint Medicines shares in Q1 2022, an estimated $548K.
Veracity Capital first reported a position in Blueprint Medicines in Q4 2019 and held it in 9 quarters.
Veracity Capital's Blueprint Medicines position peaked at $1.62M in Q4 2019.
249 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Veracity Capital's 13F filing for Q1 2022, filed 18 Apr 2022.